Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry

Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor

“…The ischemic risk is progressively decreasing in the last years thanks to a great technological improvement of the stents and of PCI techniques 15 . At the same time, the use of more potent anti-platelets therapies in ACS patients and to the ageing of patients undergoing routine treatment, the bleeding events have become prevalent and they are able to dramatically affect the prognosis of our patients [16][17][18][19] .…”

Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention

“…The 1-year risk of BARC 3 or 5 bleeding in patients with acute coronary syndrome (ACS) treated with PCI followed by prasugrel or ticagrelor in the RENAMI registry (Registry of New Antiplatelets in Patients With Myocardial Infarction; n=4424) was significantly higher in patients with World Health Organization–defined anemia compared with those without (5.4% versus 1.5%, respectively; P =0.001). 66 In a meta-analysis of 44 studies including >230 000 patients undergoing PCI, anemia (defined by World Health Organization criteria in the majority of studies) was present in 16% of patients and was associated with a 2-fold risk of subsequent bleeding (as defined in individual studies; adjusted risk ratio, 2.31 [95% CI, 1.44–3.71]), as well as an increased risk of ischemic events and mortality. 67 Furthermore, bleeding risk increased with increasing severity of anemia.…”

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk

“…Anemia correlates with the risk of future bleeding in patients undergoing PCI. The 1-year risk of BARC 3 or 5 bleeding in patients with acute coronary syndrome (ACS) treated with PCI followed by prasugrel or ticagrelor in the RENAMI registry (Registry of New Antiplatelets in Patients With Myocardial Infarction; n=4424) was significantly higher in patients with World Health Organization–defined anemia compared with those without (5.4% versus 1.5%, respectively; P =0.001) 66 . In a meta-analysis of 44 studies including >230 000 patients undergoing PCI, anemia (defined by World Health Organization criteria in the majority of studies) was present in 16% of patients and was associated with a 2-fold risk of subsequent bleeding (as defined in individual studies; adjusted risk ratio, 2.31 [95% CI, 1.44–3.71]), as well as an increased risk of ischemic events and mortality 67 .…”